Crispr Therapeutics Ag (CRSP)

R&D to Revenue

7559.17%

Fiscal year · Period ending:

CRSP logo

CRSP R&D to Revenue

Latest reported7559.17%
CRSP FY R&D/Revenue (0.00% → 7559.17%)
High-resolution chart · PNG

CRSP r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Crispr Therapeutics Ag R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
7,559.1738%
916.1514%
104.6843%
105,881.8807%
37.2987%
30,790.2643%
61.9365%
3,641.9014%
170.2564%
817.9318%
5,090.2834%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.